3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Gastrointestinal
1
Conditions
Triple Negative Breast Neoplasms
4
Neoplasm Metastasis
4
Carcinoma, Non-Small-Cell Lung
4
Pancreatic Neoplasms
3
Head and Neck Neoplasms
3
Biliary Tract Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
2
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasms
2
Esophageal Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Hepatocellular
2
Breast Neoplasms
2
Turcot syndrome
1
Solid Tumor, Adult
1
Rectal Neoplasms
1
Melanoma
1
Lung Neoplasms
1
Liver Neoplasms
1
Hyperthermia
1
Histiocytoma, Malignant Fibrous
1
Glioma
1
Esophageal Squamous Cell Carcinoma
1
Endometrial Neoplasms
1
Efficacy
1
Digestive System Neoplasms
1
Dermatofibrosarcoma
1
Colonic Neoplasms
1
Carcinoma, Transitional Cell
1
Interventions
pembrolizumab
3
Nivolumab
2
sintilimab
1
regorafenib
1
denileukin diftitox
1
Radiation Dose Hypofractionation
1
Ipilimumab
1
Interleukin-2
1
Immune Checkpoint Inhibitors
1
E7777 fusion protein
1
Clinical Trials, Phase II as Topic
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Turcot syndrome
×
Immune Checkpoint Inhibitors
×
Clear all
NCT06710847
2026-02-02
SYLVER
GlaxoSmithKline
Phase 1/2
Active not recruiting
14 enrolled